Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Athens Medical CentreFRA:ACS +2.11%63 EV-to-EBIT is 35.27 as of Aug. 01, 2026, which is 113% above its 10-year median of 16.55. GuruFocus rates FRA:ACS with a GF Score™ of 63/100 and a GF Value™ of €1.78. The stock has 9 warning signs investors should review. Among 471 Healthcare Providers & Services companies, Athens Medical Centre ranks worse than 81.1% on this metric.
The historical rank and industry rank for Athens Medical Centre's EV-to-EBIT or its related term are showing as below:
FRA:ACS'
s EV-to-EBIT Range Over the Past 10 Years
Min: -24.95 Med: 16.55 Max: 39.22
Current: 35.26
During the past 13 years, the highest EV-to-EBIT of Athens Medical Centre was 39.22. The lowest was -24.95. And the median was 16.55.
FRA:ACS's EV-to-EBIT is ranked worse than 81.1% of 471
companies
in the Healthcare Providers & Services industry
Industry Median: 15.84
vs FRA:ACS: 35.26
Athens Medical Centre (FRA:ACS) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Athens Medical Centre's Enterprise Value for the quarter that ended in Dec. 2025 was €301.9 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Athens Medical Centre's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was €8.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Care Facilities subindustry, Athens Medical Centre's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Athens Medical Centre EV-to-EBIT vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Athens Medical Centre's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Athens Medical Centre's EV-to-EBIT falls into.
Athens Medical Centre's current Enterprise Value is €294.1 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Athens Medical Centre's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was €8.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Athens Medical Centre (FRA:ACS) has a EV-to-EBIT of 35.27 as of Aug. 01, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Athens Medical Centre and its competitors. This is 113% above median its historical median of 16.55. According to the industry distribution chart, Athens Medical Centre ranks #382 out of 471 companies in the Healthcare Providers & Services industry, placing it in the top 81.1%.
Is Athens Medical Centre's EV-to-EBIT too high?
Athens Medical Centre's current EV-to-EBIT of 35.27 is 113% above median its 10-year median of 16.55. The Healthcare Providers & Services industry median EV-to-EBIT is 15.84. Athens Medical Centre's value of 35.27 is 122.7% above this industry median. Based on the distribution chart, Athens Medical Centre ranks #382 out of 471 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Athens Medical Centre has a GF Score™ of 63/100, reflecting its overall financial health beyond just this single metric.
How does Athens Medical Centre's EV-to-EBIT compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Athens Medical Centre ranks #382 out of 471 companies for EV-to-EBIT. This places Athens Medical Centre in the lower half of its industry. The industry median EV-to-EBIT is 15.84. Athens Medical Centre's value of 35.27 is 122.7% above this benchmark. While the company's 10-year median is 16.55 vs. the industry median of 15.84, Athens Medical Centre has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Healthcare Providers & Services company?
The median EV-to-EBIT among Healthcare Providers & Services companies is 15.84, based on 471 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Athens Medical Centre's current EV-to-EBIT of 35.27 is 122.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Athens Medical Centre and its competitors. For the Healthcare Providers & Services industry, the median EV-to-EBIT is 15.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Athens Medical Centre's current EV-to-EBIT is 35.27, which is 113% above median its own 10-year median of 16.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Athens Medical Centre stock overvalued right now?
Athens Medical Centre (FRA:ACS) has a current EV-to-EBIT of 35.27. The stock's GF Value™ is €1.78, compared to a current price of €1.45 — trading 18.5% below its estimated fair value. The current EV-to-EBIT is 35.27, which is 113% above median its 10-year median of 16.55 and 122.7% above the Healthcare Providers & Services industry median of 15.84. Athens Medical Centre's overall GF Score™ is 63/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Athens Medical Centre (FRA:ACS), the current EV-to-EBIT is 35.27 as of Aug. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Athens Medical Centre (FRA:ACS) Overvalued in 2026?
Based on GuruFocus' analysis, Athens Medical Centre stock appears to be undervalued.
The current stock price of €1.45 is trading 18.5% below its estimated GF Value™ of €1.78.
Key valuation signals for FRA:ACS:
EV-to-EBIT: 35.27 (113% above median its 10-year median of 16.55)
GF Value™: €1.78 vs. price of €1.45 (18.5% below fair value)
Industry Position: 122.7% above the Healthcare Providers & Services median (#382 of 471)
No single metric tells the full story. See the FRA:ACS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Athens Medical Centre SA engages in the provision of healthcare services. It includes medical research and methods of treatment, training, and selection of executives and staff on behalf of the hospitals and importation of medical tools, instruments, machinery, and automated devices for the hospitals. Its offering includes medical services in such specializations as pathology, cardiology, general surgery, plastic and vascular surgery, orthopedic, physiotherapy, ophthalmology, urology, neurosurgery, thoracic, pediatric, dermatology, endocrinology and stomatology. The company operates in Domestic healthcare service, Healthcare service provided abroad (Romania) and Sale of medical tools & sanitary/health equipment segment.
63GF Score
Get the complete analysis for FRA:ACS
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:ACS has been successfully added to your 
